Cited by 318Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Pandey, Rajesh, Khuller, G.K.·2005·Tuberculosis

DOI 10.1016/j.tube.2004.11.003

Open this paper in CoChat — free account

Abstract

The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis. The SLPs prepared by the "emulsion solvent diffusion" technique possessed a favourable mass median aerodynamic diameter suitable for bronchoalveolar drug delivery. Following a single nebulization to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 5 days and in the organs (lungs, liver and spleen) for 7 days whereas free drugs were cleared by 1-2 days. The mean residence time and drug bioavailability were improved several-fold in the case of drug-loaded SLPs. A similar pharmacokinetic profile was observed in Mycobacterium tuberculosis-infected guinea pigs. On nebulization of drug-loaded SLPs to infected guinea pigs at every 7th day, no tubercle bacilli could be detected in the lungs/spleen after 7 doses of treatment whereas 46 daily doses of orally administered drugs were required to obtain an equivalent therapeutic benefit. Further, there was no evidence of any biochemical hepatotoxicity. Thus, nebulization of SLP-based antitubercular drugs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.

Integrity signals

Registry

Crossref · 10.1016/j.tube.2004.11.003

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

THIS ARTICLE HAS BEEN RETRACTEDï¿½ï¿½Aerosolised liposomal hamycin for treatment of systemic Candida infections in mice
Dhuley, J. N. (1999) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1999.tb01347.x · Cited by 4
Retracted
Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. D. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 1,008
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389
Self-citation
Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization
Hu, F., Yuan, H., Zhang, H. H., & Fang, M. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00081-9 · Cited by 284
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Self-citation
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
Videira, M. A., Botelho, M. F., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J. J., & Almeida, A. J. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000054933 · Cited by 213
Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Solid lipid nanoparticles (SLN) for controlled drug delivery
Müller, R. H., Freitas, C., Mühlen, A. Z., & Mehnert, W. (1996) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)86243-4 · Cited by 174
Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization
Jenning, V., Lippacher, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/713817583 · Cited by 163

Show all 24 references

Research works printed but not linked: 1

Scott, 1967, Fluorimetric determination of isonicotinic acid hydrazide in plasma, J Lab Clin Med, 70, 355

Sorted by citations

Items 201–300 of 316

Oral Administration of Nanoparticles-Based TB Drugs
Magalhães, J., Vieira, A. C. C., Santos, S. G., Pinheiro, M., & Reis, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52725-5.00016-2 · Cited by 13
Sterile dosage forms loaded nanosystems for parenteral, nasal, pulmonary and ocular administration
Ahmed, T. A., El‐Say, K. M., Ahmed, O. A. A., & Zidan, A. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813629-4.00009-7 · Cited by 12
Nanocarriers Against Bacterial Biofilms
Nafee, N. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801317-5.00011-6 · Cited by 12
Development and Validation of a RP-HPLC Method for Simultaneous Estimation of Antitubercular Drugs in Solid Lipid Nanoparticles
Khatak, S., Khatak, M., Ali, F., Rathi, A., Singh, R. P., Singh, G. N., & Dureja, H. (2018) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000449 · Cited by 12
Effective dual role catalyst of mixed oxide heterostructure for photocatalyst and electrocatalytic sensing of isoniazid
Dhanasekaran, T., Padmanaban, A., Manigandan, R., Kumar, S. P., Stephen, A., & Narayanan, V. (2017) · Journal of Materials Science Materials in Electronics · doi:10.1007/s10854-017-7098-9 · Cited by 12
Making the case: developing innovative adherence solutions for the treatment of tuberculosis
Verma, M., Furin, J. J., Langer, R., & Traverso, G. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-001323 · Cited by 12
Chemically Nano-Engineered Theranostics for Phytoconstituents as Healthcare Application
Gilani, S. J., Beg, S., Kala, C., Nomani, M. S., Mahapatra, D. K., Imam, S. S., & Taleuzzaman, M. (2019) · Current Biochemical Engineering · doi:10.2174/2212711906666190723144111 · Cited by 12
Formulation, Characterization, in vitro Anti-Tubercular Activity and Cytotoxicity Study of Solid Lipid Nanoparticles of Isoniazid
Mohanta, B. C., Dinda, S. C., Mishra, G., Palei, N. N., & Dusthackeer, A. (2018) · Nano Biomedicine and Engineering · doi:10.5101/nbe.v10i4.p379-391 · Cited by 11
Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics
Tram, N. D. T., & Ee, P. L. R. (2017) · Antibiotics · doi:10.3390/antibiotics6030014 · Cited by 11
Bio-Based Nanoemulsions: An Eco-Safe Approach Towards the Eco-Toxicity Problem
Mishra, P., Balaji, A. P. B., Mukherjee, A., & Chandrasekaran, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-48281-1_94-1 · Cited by 10
Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics
Khosravi, F., Rahmani, P., & Jahanban‐Esfahlan, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118551 · Cited by 13
Nanoparticle-Based Drug Delivery Systems: Promising Approaches Against Bacterial Infections
Rai, A., Comune, M., & Ferreira, L. (2019) · Springer eBooks · doi:10.1007/978-981-13-9871-1_27 · Cited by 9
Polymer–ceramic nanocomposites for controlled drug delivery
Jabeen, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813741-3.00035-2 · Cited by 9
RETRACTED: Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases
Jin, X., Song, L., Ma, C., Zhang, Y.-C., & Yu, S. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.10.012 · Cited by 10
Retracted
Measurement of the size and charge distribution of sodium chloride particles generated by an Aeroneb Pro ® pharmaceutical nebulizer
Simones, M. P., Loyalka, S. K., Duffy, C. M. C., MacLoughlin, R. J., Tatham, A., & Power, P. D. (2014) · European Journal of Nanomedicine · doi:10.1515/ejnm-2013-0018 · Cited by 9
NANOPARTICLES AS DRUG DELIVERY SYSTEM FOR ANTITUBERCULOUS DRUGS
Sanzhakov, M. A., Ipatova, O. M., Torkhovskaya, T. I., Prozorovskii, V. N., Tikhonova, E. G., Druzhilovskaya, O. S., & Medvedeva, N. V. (2013) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v68i8.722 · Cited by 9
Toxicity Concerns of Nanocarriers
Tavakol, S., Kiani, V., Tavakol, B., Derakhshan, M. A., Joghataei, M. T., & Rezayat, S. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809717-5.00016-6 · Cited by 9
Nanostructure Drug Delivery System Is an Option to Solve Antimicrobial Drug Resistance
Patil, J., Dhadde, S. B., & Chandakavathe, B. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814031-4.00007-6 · Cited by 9
Nano-strategies used for combatting the scourge of tuberculosis infections
Fang, R., Jin, Y., Kong, W., Wang, H., Wang, S., Li, X., Xing, J., Zhang, Y., Yang, X., & Song, N. (2024) · Discover Immunity. · doi:10.1007/s44368-024-00007-y · Cited by 8
Studies in Development and Statistical Optimization of Levofloxacin Solid Lipid Nanoparticles for the Treatment of Tuberculosis
Shah, S. R., Shah, N. R., Amin, S., Mori, D., Soniwala, M. M., & Chavda, J. R. (2022) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-022-09617-1 · Cited by 8
Natural carriers for application in tuberculosis treatment
Costa, H., & Grenha, A. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2012.726283 · Cited by 8
Lipid Nanoparticle Formulations for Enhanced Antituberculosis Therapy
Banerjee, S., & Pillai, J. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47347-7.00011-2 · Cited by 8
New Trends in the Antimicrobial Agents Delivery Using Nanoparticles
Bermúdez, J. M., Cid, A. G., Romero, A. I., Villegas, M., Villegas, N. Á., & Palma, S. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52733-0.00001-x · Cited by 8
Nanoparticles in Drug Delivery Systems
Castro, E., & Kumar, A. (2013) · CRC Press eBooks · doi:10.1201/b14802-4 · Cited by 8
A REVIEW ON PROMISING ANTIBIOTIC THERAPY BY NOVEL DELIVERY SYSTEMS
Priyanka, R., & Bhattacharyya, S. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i5.23999 · Cited by 8
A hydrogel-based implantable multidrug antitubercular formulation outperforms oral delivery
Pal, S., Soni, V., Kumar, S., Jha, S. K., Medatwal, N., Rana, K., Yadav, P., Mehta, D., Jain, D., Sharma, P., et al. (2021) · Nanoscale · doi:10.1039/d0nr08806d · Cited by 8
Inhalational Delivery of β‐glucan‐chitosan‐poly(lactic co‐glycolic) acid Nanoparticles Enhance Alveolar Macrophage Rifampin Concentrations for the Treatment of Tuberculosis
Kutscher, H. L., Tamblin, M., Karki, S., Chaves, L. D., Baird, M., Parvin, A., Smith, E., Dube, A., Zhang, Z., Chakraborty, S., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400057 · Cited by 7
Targeted delivery of antitubercular drugs using glucan lipid particles
Jaecklein, E., Papavinasasundaram, K. G., Ostroff, G. R., Sassetti, C. M., & Soto, E. R. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02744-24 · Cited by 7
Inhalation-Based Nanoparticle Drug Delivery Targeting the Diseased Lower Airways in Idiopathic Pulmonary Fibrosis
Lee, J. W., Skibba, M. E., Tang, T., Noh, H., Brasier, A. R., & Hong, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020168 · Cited by 7
Application of Nanotechnology in Immunity against Infection
Zhang, J., Shi, W., Ma, Q., Cui, H., & Zhang, L. (2021) · Coatings · doi:10.3390/coatings11040430 · Cited by 7
The quest to deliver high-dose rifampicin: can the inhaled approach help?
Khadka, P., Dummer, J. F., Hill, P. C., & Das, S. C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2301931 · Cited by 7
Nanostructured lipid carrier-based drug delivery systems for tuberculosis treatment
Carneiro, S. P., & dos Santos, O. D. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00012-6 · Cited by 7
Recent advances on Metal oxide-polymer systems in targeted therapy and diagnosis: Applications and toxicological perspective
Kumar, N., Tyeb, S., & Verma, V. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102814 · Cited by 7
Solid lipid nanoparticles for the delivery of drug molecules
Giri, T. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818433-2.00016-9 · Cited by 6
The effect of radiolabeled nanostructured lipid carrier systems containing imatinib mesylate on NIH-3T3 and CRL-1739 cells
Gündoğdu, E., Demir, E. S., Ekinci, M., Özgenç, E., İlem‐Özdemir, D., Şenyiğit, Z. A., & Aşıkoğlu, M. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1841337 · Cited by 6
Quality by Design (QbD) driven Systematic Development of Nano-lipoidal Carrier of Poorly Water Soluble Anti-tubercular agent-Rifabutin.
Patil, S. R., Gattani, S., Nirbhavane, P., Katare, O. P., & Patil, K. D. (2021) · Materials Technology · doi:10.1080/10667857.2020.1870327 · Cited by 6
Development of Lipid Nanocarriers for Tuberculosis Treatment: Evaluation of Suitable Excipients and Nanocarriers
Hädrich, G., Vaz, G. R., Boschero, R. A., Appel, A. S., Ramos, C., Halicki, P. C. B., Bidone, J., Teixeira, H. F., Muccillo-Baisch, A. L., Dal‐Bó, A. G., et al. (2021) · Current Drug Delivery · doi:10.2174/1567201818666210212092112 · Cited by 6
Drug Resistance in Tuberculosis: Nanomedicines at Rescue
Kumar, N., Das, B., & Patra, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52733-0.00010-0 · Cited by 5
2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Sawarkar, S. P., Prabhu, P., Fernandes, T., Damani, M., Chaubey, P., & Narayanan, S. (2021) · Current Drug Delivery · doi:10.2174/1567201819666211216141942 · Cited by 5
Nanomedicine in infectious disease challenges and regulatory concerns
Das, U., Bala, A., Molla, R., & Mandal, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13337-4.00012-4 · Cited by 5
Approaches for designing and delivering solid lipid nanoparticles of distinct antitubercular drugs
Vasam, M., & Goulikar, R. K. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2144791 · Cited by 5
Nanoformulations for the Therapy of Pulmonary Infections
Dhoble, S., Ghodake, V. N., Chogale, M. M., & Patravale, V. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46152-8.00020-2 · Cited by 5
Nanoweapons Against Tuberculosis
Jampílek, J., & Kráľová, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_21 · Cited by 5
Nanomedicine for tuberculosis: Insights from animal models
Ahmad, Z., Maqbool, M. U., & Raja, A. (2011) · International journal of nanodimension. · doi:10.7508/ijnd.2011.01.009 · Cited by 5
Controlled drug release from lung-targeted nanocarriers via chemically mediated shell permeabilisation
Chen, H., Woods, A., Forbes, B., & Jones, S. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.012 · Cited by 5
Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs
Jadhav, M., Khan, T. A., Bhavsar, C., Momin, M. M., & Omri, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1621287 · Cited by 5
Testing Inhaled Drug Therapies for Treating Tuberculosis
Young, E., Hickey, A. J., & Braunstein, M. (2016) · doi:10.1002/9781118943182.ch6 · Cited by 5
From Nature to Nanotech: Customizing Essential Oil Delivery for a Reduced Fungicide in Agriculture
Terra, M. C., Campos, E. V. R., Preisler, A. C., Pereira, A. D. E. S., de Oliveira, J. L., & Fraceto, L. F. (2025) · ACS Omega · doi:10.1021/acsomega.5c07651 · Cited by 5
Nucleic Acid-Based Nanocarriers
Chakraborty, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814033-8.00005-9 · Cited by 4
Is particle size reduction linked to drug efficacy: an overview into nano initiatives in pharmaceuticals
Sher, M., Zahoor, M., Shah, S. W. A., & Khan, F. A. (2023) · Zeitschrift für Physikalische Chemie · doi:10.1515/zpch-2023-0221 · Cited by 4
Bio-based Nanoemulsions: An Eco-safe Approach Towards the Eco-toxicity Problem
Mishra, P., Balaji, A. P. B., Mukherjee, A., & Chandrasekaran, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-68255-6_94 · Cited by 4
Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival
Pereira, L. P., Diogo, J., Mateus, R., Pimentel, M., & Videira, M. (2015) · Journal of Nanoparticle Research · doi:10.1007/s11051-015-2892-x · Cited by 4
Lipidic Micro‐ and Nano‐Carriers for Pulmonary Drug Delivery—A State‐of‐the‐Art Review
Rahimpour, Y., Hamishehkar, H., & Nokhodchi, A. (2015) · doi:10.1002/9781118799536.ch6 · Cited by 4
Research advances of liposomes and exosomes in drug delivery and biomarker screening
Su, Y., Qian, X., & Qin, W. (2025) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2024.08012 · Cited by 3
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3
Understanding the Pharmacology and Pharmacotherapeutics for Infectious Diseases
Agrawal, N., Singh, I. P., Khanna, M., Dhawan, G., Kumar, P., & Dhawan, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_3 · Cited by 3
A Comprehensive Study of Multi-Drug Resistance in Tuberculosis
Sharma, M., & Kansal, S. (2022) · Advances in medical education, research, and ethics (AMERE) book series · doi:10.4018/978-1-7998-8490-3.ch016 · Cited by 3
Solid lipid nanoparticle a complete tool for brain targeted drug delivery
Ramalingam, P., Dutta, G., Mothilal, M., & Sugumaran, A. (2025) · Current Issues in Pharmacy and Medical Sciences · doi:10.12923/cipms-2025-0002 · Cited by 3
Tuberculosis and Nanotechnology: Where shall the Twain meet?
Shafiq, N., Malhotra, S., & Kondel, R. (2013) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1084 · Cited by 3
The Use of Nanoparticles for Antimicrobial Delivery
Moreno-Sastre, M., Pastor, M., Esquisabel, A., & Pedraz, J. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-28368-5_17 · Cited by 3
Nanotechnology Applications for Infectious Diseases
Tobin, E. H. (2013) · CRC Press eBooks · doi:10.1201/b15642-2 · Cited by 3
A concise review on nanoscale carriers to target intracellular infections
Maithania, H. V., & Gundeti, M. (2026) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-026-00038-4 · Cited by 2
Revolutionizing Antibacterial Strategies: Lipid Nanoparticles as Game-changers in Combatting Multi-drug-resistant Infections
p, R., Prajapati, B. G., Rajeshkumar, R., Balasubramaniam, V., & Ponnusankar, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673314366240712105637 · Cited by 2
Recent approaches for the treatment of multidrug resistance tuberculosis
Singh, M., Banjare, N., Chauhan, A. S., & Gupta, P. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24035-5.00013-x · Cited by 2
Nanopharmaceuticals
Yurdasiper, A., Arıcı, M., & Özyazıcı, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40016-9.00007-5 · Cited by 2
Lipid nanoparticles for the treatment of neglected tropical diseases
Barbosa, R. D. M., Meirelles, L. M. A., García‐Villén, F., Câmara, G. B. M., Finkler, C. L. L., Viseras, C., & Raffin, F. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821100-7.00020-0 · Cited by 2
Accessing BCG in infected macrophages by antibody-mediated drug delivery system and tracking by surface-enhanced Raman scattering spectroscopy
Lima, F. R. A., Campos, L. C., Macedo, G. C., Avila, H. D., & Sant’Ana, A. C. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119660 · Cited by 2
Nanocarriers as pulmonary drug delivery systems
Gad, S., Yousry, A., Hassan, T. H., & Aidy, S. (2022) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2022.143936.1150 · Cited by 2
Evaluation of Lung Toxicity of Biodegradable Nanoparticles
Grabowski, N., Hillaireau, H., Vergnaud, J., & Fattal, E. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_22 · Cited by 2
Amphotericin B as a mycolic acid specific targeting agent in tuberculosis
Benadie, Y. (2007) · UpSpace Institutional Repository (University of Pretoria) · Cited by 2
Addressing Unmet Medical Needs Using Targeted Drug‐Delivery Systems: Emphasis on Nanomedicine‐Based Applications
Pardeshi, C. V., Sonawane, R. O., & Bachhav, Y. G. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch2 · Cited by 2
Antibacterial Drug Development Using Starch Nanoparticles
Bera, S. (2023) · Current Nanomaterials · doi:10.2174/0124054615271640231122034023 · Cited by 1
Current Advances in Lipid-Based Drug Delivery Systems as Nanocarriers for the Management of Female Genital Tuberculosis
Chavan, D. D., Bhosale, R. R., Thorat, V. M., Yadav, A. R., Patil, S. V., Janugade, B. U., & Patil, S. J. (2024) · Cureus · doi:10.7759/cureus.74452 · Cited by 1
EFFECT OF A PARTICLE ENGINEERING PROCESS ON POLYMORPHIC TRANSITION OF PYRAZINAMIDE
Gad, S. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 1
Nanotechnology Applications for Infectious Diseases
Tobin, E. H., & MD, M. (2013) · CRC Press eBooks · doi:10.1201/b15642-5 · Cited by 1
FORMULATION AND DEVELOPMENT OF FLUOXETINE TRANSDERMAL PATCHES: IN VITRO AND IN VIVO EVALUATION
Singh, D., & Chandra, A. (2016) · International Journal of Pharmaceutical Research and Innovation · doi:10.20530/ijpri_9_1-8 · Cited by 1
Tuberculosis
Bhatia, S. K. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6920-0_8 · Cited by 1
Lipid-Based Nanocarriers and Applications in Medicine
Aydın, Ü. F., & Tuli, A. (2023) · Recent advances in biotechnology · doi:10.2174/9789815179422123080005 · Cited by 1
Futuristic Potential of Nanoantibiotics Against Multidrug Resistant Tuberculosis
Khairnar, P., Singh, A., & Shukla, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_18 · Cited by 1
Nano particles as drug delivery agents for antitubercular drugs
Aditi, & Qanungo, K. (2023) · AIP conference proceedings · doi:10.1063/5.0112810 · Cited by 1
Veterinary Nanomedicine Delivery System for Mastitis
Nanjwade, B. K. (2023) · Nanomedicine & Nanotechnology Open Access · doi:10.23880/nnoa-16000239 · Cited by 1
Inhaled Drug Combinations
Pandya, S. M., Gupta, A., Ranjan, R., Sachan, M., Agrawal, A. K., & Misra, A. (2016) · Wiley eBooks · doi:10.1002/9781118943182.ch11 · Cited by 1
SYMMETRICAL 1,3-DIGLYCERIDES AS SOLID LIPID MICROPARTICLES FOR CONTROLLED DRUG DELIVERY
Yazdi, S. (2007) · eCommons (Cornell University)
Desenvolvimento de micropartículas poliméricas carreando um análogo sintético de neolignana para o uso na terapia da Tuberculose
Minarini, P. R. R. (2006) · doi:10.11606/t.60.2006.tde-16012007-163124
Challenges Facing Antitubercular Therapy: New Drugs and Delivery Systems
Chandrashekarappa, T. G., & Suresh, S. (2007) · Clinical Research and Regulatory Affairs · doi:10.1080/10601330701695333
Nanoencapsulation of Antitumor and Antituberculosis Drug Preparations with Biocompatible Polymers
Burkeev, M. Z., Kreuter, J., van Herk, A. M., Tazhbayev, Y. M., Zhaparova, L. Z., Zhumagalieva, T. S., & Zhappar, N. K. (2014) · Journal of Research Updates in Polymer Science · doi:10.6000/1929-5995.2014.03.02.2
Solid lipid particles for improved dermal delivery of virgin coconut oil
Noor, N. M. (2013)
UPDATE ON NOVEL TARGETED DRUG DELIVERY SYSTEMS
Bhandarkar, A. P., Aarthy, R., & Devasrita, D. (2015)
Nanomedicines for the treatment of tuberculosis
Donnellan, S. (2016)
Targeting Drug-Resistant Tuberculosis Using SMART Nanotechnology Approach
Al-Shammaa, Z. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
SOLID LIPID NANOPARTICLES: A NOVEL POTENTIAL CARRIER APPROACH
Rewar, S., Mirdha, D., & Rewar, P. (2014)
Overcoming Antimicrobial Resistance: New Strategies, Expections: Greater Hope
Sadiku, E. R. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.13.002353
Nanomedicine progress in prevention, detection, and treatment of tuberculosis
Marutescu, L. G., Frăţiean, D., & Chifiriuc, M. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816505-8.00011-4
Microparticle fabricated from a series of symmetrical lipids based on dihydroxyacetone form textured architectures
Yazdi, S., Chen, D. J., & Putnam, D. A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.012
Approaches toward designing nanocarriers for tuberculosis drug delivery
Mehnath, S., & Jeyaraj, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00012-7
An Overview of New Strategies Based on Functional Nanoscale Materials to the Treatment of Tuberculosis
de Assis, L. C., de Castro, A. A., Ramalho, T. C., Taft, C. A., & Porta, F. A. L. (2021) · Engineering materials · doi:10.1007/978-3-030-62226-8_19
Nanotechnology and COVID-19: Potential Application for Treatment Sona Talaei, Hassan Mellatyar, Shiva Mohammadi, Yunes Panahi, Parisa Kianpour, Abolfazl Akbarzadeh, Nosratollah Zarghami
Talaei, S., Mellatyar, H., Mohammadi, S., Panahi, Y., Kianpour, P., Akbarzadeh, A., & Zarghami, N. (2020) · EURAS Journal of Health · doi:10.17932/ejoh.2020.022/ejoh_v02i1001
Controlled Drug Delivery via the Lung
Ramírez-Rigo, M. V., Ceschan, N. E., & Smyth, H. D. C. (2021) · doi:10.1002/9781119769644.ch18
Application of Nanoemulsion in Tuberculosis Treatment
Singh, S. K., Murti, Y., & Agrawal, N. (2021) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-7998-8378-4.ch008 · Cited by 1
Desenvolvimento e caracterização de micropartículas de quitosana para administração pulmonar de isoniazida
de Oliveira, P. M. (2016) · doi:10.26512/2016.07.d.21624

Authors: Pandey, R., & Khuller, G. K.
Affiliations: Post Graduate Institute of Medical Education and Research (IN)
Corresponding author: Khuller, G.K.
ORCID: Pandey, Rajesh
Venue: Tuberculosis
Publisher: Elsevier BV
Published: 2005-07
Volume: 85
Issue: 4
Pages: 227-234
ISSN: 1472-9792 (ISSN-L)
DOI: 10.1016/j.tube.2004.11.003
OpenAlex: W2137397041
Cited by: 318
References: 24
Citations by year: 2026: 5 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 18 · 2019: 19 · 2018: 24 · 2017: 18 · 2016: 24 · 2015: 13 · 2014: 26 · 2013: 20 · 2012: 14
FWCI: 7.42
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Tuberculosis (publishedVersion)
PubMed (publishedVersion)
Funders: Department of Science and Technology, Ministry of Science and Technology, India
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: solid lipid particles, pulmonary tuberculosis, nebulized drug delivery, rifampicin, isoniazid, pyrazinamide, antitubercular agents, emulsion solvent diffusion, aerosol drug delivery, pharmacokinetics, drug bioavailability, Mycobacterium tuberculosis, guinea pig model, hepatotoxicity
MeSH terms: Administration, Inhalation, Animals, Antitubercular Agents, Biological Availability, Drug Carriers, Guinea Pigs, Isoniazid, Lipids, Pyrazinamide, Rifampin, Tuberculosis, Drug Delivery Systems, Area Under Curve, Nanostructures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks